The UroLift 2 System with ATC (UroLift 2 ATC) has received FDA clearance, marking a significant advancement in BPH care. The recent development is also expected to significantly enhance Teleflex ...

Urolift is a minimally invasive procedure to help treat an enlarged prostate, known as benign prostatic hyperplasia (BPH). Medicare will typically cover Urolift procedures when a doctor deems them ...

UroLift is a minimally invasive treatment option for benign prostatic hyperplasia (BPH), also called enlarged prostate. Medicare covers the UroLift procedure when a doctor deems it medically ...

RBC Capital downgraded Teleflex to Sector Perform, lowering the price target to $155 from $220, pointing to the company’s ...

After seeing a urologist and having a UroLift, a surgery that relieves pressure on the urethra, Braeden was later diagnosed with cancer and learned he had both low-grade and high-grade cancer cells.

Near-term growth is limited to 1%-2% due to UroLift challenges and inventory management headwinds. Teleflex announced a major strategic pivot, planning to separate into two independent publicly ...

Raymond James downgraded Teleflex (TFX) to Market Perform from Outperform without a price target The firm likes the company’s active portfolio ...